Literature DB >> 27016707

Novel spiropyrazolone antitumor scaffold with potent activity: Design, synthesis and structure-activity relationship.

Shanchao Wu1, Yu Li1, Guixia Xu2, Shuqiang Chen1, Yongqiang Zhang1, Na Liu1, Guoqiang Dong1, Chaoyu Miao1, Hua Su3, Wannian Zhang4, Chunquan Sheng5.   

Abstract

Phenotypic screening of high quality compound library is an effective strategy to discover novel bioactive molecules. Previously, we developed the divergent organocatalytic cascade approach to efficiently construct a focused library with scaffold diversity and successfully identified a novel spiropyrazolone antitumor scaffold. Herein, a series of spiropyrazolone derivatives were designed, synthesized and assayed. Most of them showed good in vitro antitumor activity with a broad spectrum. Preliminary structure-activity relationship for the substitutions and the stereo configuration were obtained. Compound 5k showed good antitumor activity and could effectively induce cancer cell apoptosis, which represents a good starting point for the development of novel antitumor agents.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antitumor; Cancer cell apoptosis; Spiropyrazolone; Structure–activity relationship

Mesh:

Substances:

Year:  2016        PMID: 27016707     DOI: 10.1016/j.ejmech.2016.03.039

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  Synthesis of new Spiropyrazole derivatives under microwaves irradiation and docking study for inhibition the microbes and COVID-19.

Authors:  Ghada S Masaret
Journal:  J Mol Struct       Date:  2022-06-25       Impact factor: 3.841

2.  Stretchable chiral pockets for palladium-catalyzed highly chemo- and enantioselective allenylation.

Authors:  Yuchen Zhang; Xue Zhang; Shengming Ma
Journal:  Nat Commun       Date:  2021-04-23       Impact factor: 14.919

3.  Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models.

Authors:  Long Chen; Jing Zhang; Xinjing Wang; Yu Li; Lu Zhou; Xiongxiong Lu; Guoqiang Dong; Chunquan Sheng
Journal:  Acta Pharm Sin B       Date:  2021-07-19       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.